Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gilead Sciences, Inc.
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
June 6th, 2009
Gilead Sciences, Inc. (Nasdaq:GILD) announced that it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and of Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), and are licensed exclusively to Gilead Sciences by Emory University. The lawsuit is based on an Abbreviated New Drug Application filed by Teva Pharmaceuticals USA, Inc., which seeks approval to manufacture...
Source: Law & Health Weekly (2009-06-06)
|
